News

An Interview with Martino Laurenzi, M.D., MPH

Clinical Research Scientist for the TB Alliance

This video was recorded on November 13, 2009 at Johns Hopkins University.

Dr. Martino Laurenzi
Dr. Martino Laurenzi

Dr. Laurenzi, an expert in clinical development and community health, is a Clinical Research Scientist at the TB Alliance, where his responsibilities include the oversight of clinical trials. Dr. Laurenzi has long been involved in public health research; the Gubbio Study, which he started in 1982 in the Italian town for which it is named, is one of the longest standing population-based epidemiological studies for the screening of cardiovascular risk factors.

Prior to joining the TB Alliance, Dr. Laurenzi spent twenty-five years at Merck & Co., most recently as Executive Medical Director, Specialty Products. While at Merck, he managed protocol development and implementation for a wide range of projects in several therapeutic areas, and provided medical input and guidance to clinical research programs from Phase II through Phase V trials. He was also extensively involved in Clinical Research Operations, and managed Merck Research Laboratories’ Medical Departments in the Middle European Region and in Middle East Africa. From 1990-1993 Dr. Laurenzi was Director, Medical Affairs and Epidemiology, at Merck’s facility in Rome, Italy. Since 1987, Dr. Laurenzi has served as an Adjunct Assistant Professor in the Department of Community Health and Preventive Medicine at Northwestern University.

Born in the U.S., Dr. Laurenzi grew up in Italy, where he received his Doctorate of Medicine and Surgery from the University of Rome. He obtained his Masters of Public Health from Columbia University in 1981. His research and his interests have led him to many different countries. He has lived in the U.S. since 1993.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...